The move solidifies Vermont as the first state to legalize such an action to combat high drug costs.
While the bill garnered large support from Vermont’s Democratic-controlled legislature, the state faces a few more obstacles before its wholesale importation program can take effect. Vermont still needs to design a funding mechanism for the program and submit a certification request to HHS by July 2019.
Gaining HHS’ certification may prove difficult, as many of President Donald Trump’s top health appointees believe drug importation is not a realistic — or safe — solution to high drug costs.
“The United States has the safest regulatory system in the world. The last thing we need is open borders for unsafe drugs in search of savings that cannot be safely achieved,” HHS Secretary Alex Azar said in a May 14 speech. “You can’t improve competition and choice in our drug markets with gimmicks like these — you have to boost competition and price transparency.”
Several other states have introduced drug importation legislation, but most of the bills have stalled in 2018.
More articles on supply chain:
Meet the 10 participants in the US drone program
FDA issues EpiPen shortage alert: 6 things to know
A new pharma giant —Takeda acquires Shire for $62B
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.